Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 27, 2026, titled "Press Release for Audited Financial Results for quarter and year ended March 31, 2026".
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jagsonpal Pharmaceuticals reported Q4FY26 revenue of ₹642 Mn, up 9.6% YoY, with PAT rising 31% to ₹88 Mn. Full-year FY26 revenue grew 6.9% to ₹2,872 Mn while operational PAT climbed 19% to ₹446 Mn. EBITDA margins were largely flat, slipping modestly to 21.2% (FY26) and 16.4% (Q4) on a pre-ESOP basis. The company announced a ₹40 Cr buyback at ₹250 per share (16 lakh shares, 2.4% of equity, promoters not participating) and a 200% dividend (including 75% special dividend). Cash position stood strong at ₹191 Cr. The company outpaced the Indian pharmaceutical market, growing 12.2% vs IPM's 8.6%.
Positive for shareholders — the buyback at a ~40% premium to market and higher dividend signal strong capital return, while the 19% PAT growth and market outperformance reinforce confidence. Margin guidance of 100-150 bps improvement for FY27 should support earnings momentum.